This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The immunosuppressant tacrolimus (FK 506) is widely used in transplantation medicine, although it has neurotoxic side effects. The neurotoxicity of tacrolimus to the CNS consists mainly of leukoencephalopathy with clinical and radiologic features similar to posterior reversible encephalopathy syndrome (PRES).1 The neurologic symptoms and signs of leukoencephalopathy usually develop within 3 months of commencing treatment with tacrolimus.1 We describe a patient who developed tumefactive inflammatory demyelinating lesions as an atypical manifestation of tacrolimus neurotoxicity.
Case report.
A 54-year-old woman with hepatocellular carcinoma underwent cadaver liver transplantation in May 2009. After transplantation, she was treated with tacrolimus 0.075 mg/kg and mycophenolate mofetil 250 mg BID. In September 2009, she developed slurred speech and right-side weakness 2 days before admission. Brain MRI scanned 2 days after symptoms onset showed 2 large mass-like lesions in the left corona radiata and frontal lobe. The lesions were hyperintense on T2-weighted images with an open ring pattern on gadolinium enhancement (figure,A). The serum tacrolimus level was 8.5 ng/mL (therapeutic range 5.0–15.0 ng/mL). The CSF analysis showed normal cell count, but elevated total protein level (103 mg/dL). Oligoclonal bands were absent and …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
